(Q36802699)

16 August 2017

1 reference

title

Treatment of acquired hemophilia A. (English)

1 reference

16 August 2017

0 references

0 references

1 reference

Collins PW

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Journal of Thrombosis and Haemostasis

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

893-900

1 reference

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

A population based, unselected, consecutive cohort of patients with acquired haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Thromboelastography and recombinant factor VIIa-hemophilia and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

DDAVP in acquired hemophilia A: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Successful treatment of acquired factor VIII inhibitor with cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired hemophilia due to factor VIII inhibitors in 34 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired haemophilia in South Australia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired haemophilia: experience of two Italian centres with 17 new cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired haemophilia in the elderly is a severe disease: report of five new cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Oral immunosuppressive therapy for acquired hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired haemophilia: experiences with a standardized approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired haemophilia - a study of ten cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Successful treatment of acquired hemophilia with oral immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired factor VIII inhibitors in nonhemophilic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Postpartum acquired factor VIII inhibitors: results of a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VII:C inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Acquired anti-FVIII inhibitors in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Prednisone and low-dose activated prothrombin complex concentrates for FVIII inhibitor in nonhaemophilic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Postpartum inhibitor to factor VIII: treatment with high-dose immunoglobulin and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

Treatment and outcome of acquired haemophilia A with a standard conventional regimen in a cohort without associated conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02433.X

10.1111/J.1538-7836.2007.02433.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference